广东医学2017，Vol.38Issue(21)：3350-3352,3356,4.
雷利度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤的疗效
Efficacy analysis of lenalidomide combined with rituximab in recurrent follicular lymphoma
摘要
Abstract
Objective To evaluate the efficacy and safety of lenalidomide combined with rituximab in recurrent follicular lymphoma .Methods A randomized controlled trial on 23 patients with recurrent follicular lymphoma were con-ducted, with follow-up until April 2016.The participants were divided into two groups , simple treatment group (lenalidomide 15mg/d alone) and combination group (lenalidomide 15 mg/d plus rituximab 375 mg/m2/week).Results Ten cases were assigned into Simple treatment group , and 13 into combined treatment group .Amogn them, 8 (80%) cases in simple treatment group and 10 (76.9%) cases in combined treatment group completed 12 cycles of treatment .There was no significant difference of clinical remission between the two groups (70% vs.84.6%, P=0.401).Adverse reactions included neutropenia (80% vs.76.9%, P=0.704), fatigue (40% vs.46.2%, P=0.768), thrombosis (60% vs. 15.4%, P=0.026).An average follow-up of 3 years showed that in simple treatment group the time of progress was (2.1 ±0.15) years, which was (3.5 ±0.21) years in combined treatment group (P<0.001).The survival in simple treatment group was (3.2 ±0.46) years, which was (4.7 ±0.32) years in combined treatment group (P=0.36).Conclusion The combination of lenalidomide with rituximab in treatment of recurrent follicular lymphoma is more effective and safer , providing prolonged survival and slow disease progression than lenalidomide alone.关键词
雷利度胺/利妥昔单抗/复发性滤泡性淋巴瘤Key words
lenalidomide/rituximab/recurrent follicular lymphoma引用本文复制引用
王晓平,李晖,吉晓春,张永江,杨海平..雷利度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤的疗效[J].广东医学,2017,38(21):3350-3352,3356,4.基金项目
河南省医学科技攻关计划项目(编号:201504016) （编号:201504016）
